A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy
Recruiting at62 trial locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Eli Lilly and Company
Prior Safety Data
Approved in 2 Jurisdictions
Trial Summary
What is the purpose of this trial?
The purpose of this study is to evaluate the efficacy and safety of investigational doses of dulaglutide in participants with type 2 diabetes on metformin monotherapy.
Research Team
C1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Eligibility Criteria
Inclusion Criteria
Have had type 2 diabetes (T2D) for ≥6 months according to the World Health Organization (WHO) classification
Have HbA1c of 7.0% to 10.0%, inclusive, as assessed by the central laboratory
Have been treated with stable doses of metformin for at least 3 months
See 1 more
Treatment Details
Interventions
- Dulaglutide (Glucagon-like peptide-1 receptor agonist)
- Placebo (Other)
Participant Groups
4Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Dulaglutide 4.5mgExperimental Treatment1 Intervention
4.5mg of Dulaglutide administered subcutaneously (SC)
Group II: Dulaglutide 3.0mgExperimental Treatment1 Intervention
3.0mg of Dulaglutide administered SC
Group III: Dulaglutide 1.5mgActive Control1 Intervention
1.5mg of Dulaglutide administered SC
Group IV: PlaceboPlacebo Group1 Intervention
Placebo administered SC
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Trials
2,708
Recruited
3,720,000+
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University
Related Searches
By Location